{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:59:40Z","timestamp":1794002380204,"version":"4.8.0"},"reference-count":85,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2020,9,22]]},"abstract":"<jats:p>Molecular tests for tuberculosis (TB) have the potential to help reach the three million people with TB who are undiagnosed or not reported each year and to improve the quality of care TB patients receive by providing accurate, quick results, including rapid drug-susceptibility testing. The World Health Organization (WHO) has recommended the use of molecular nucleic acid amplification tests (NAATs) tests for TB detection instead of smear microscopy, as they are able to detect TB more accurately, particularly in patients with paucibacillary disease and in people living with HIV.<\/jats:p>","DOI":"10.1128\/jcm.01582-19","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T09:32:06Z","timestamp":1596619926000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":216,"title":["Advances in Molecular Diagnosis of Tuberculosis"],"prefix":"10.1128","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9272-0985","authenticated-orcid":false,"given":"Emily","family":"MacLean","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada"},{"name":"McGill International TB Centre, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7402-5791","authenticated-orcid":false,"given":"Mikashmi","family":"Kohli","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada"},{"name":"McGill International TB Centre, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan F.","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Suresh","sequence":"additional","affiliation":[{"name":"Foundation for Innovative New Diagnostics, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6136-206X","authenticated-orcid":false,"given":"Samuel G.","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Foundation for Innovative New Diagnostics, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7216-7067","authenticated-orcid":false,"given":"Claudia M.","family":"Denkinger","sequence":"additional","affiliation":[{"name":"McGill International TB Centre, McGill University, Montreal, Canada"},{"name":"Department of Infectious Diseases, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3667-4536","authenticated-orcid":false,"given":"Madhukar","family":"Pai","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada"},{"name":"McGill International TB Centre, McGill University, Montreal, Canada"},{"name":"Manipal McGill Program for Infectious Diseases, Manipal Academy of Higher Education, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Global tuberculosis report 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Global tuberculosis report 2019. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","volume-title":"WHO End TB Strategy","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. WHO End TB Strategy. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_4_2","volume-title":"The potential impact of the COVID-19 response on tuberculosis in high-burden countries: a modelling analysis","author":"Stop TB Partnership","year":"2020","unstructured":"Stop TB Partnership. 2020. The potential impact of the COVID-19 response on tuberculosis in high-burden countries: a modelling analysis. Stop TB Partnership, Geneva, Switzerland."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0230"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62073-5"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0380-2"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034-13"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu821"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu682"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00543-2016"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.12842.2"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.13112.1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.25956"},{"key":"e_1_3_2_15_2","volume-title":"Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis: policy statement","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis: policy statement. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_16_2","volume-title":"The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_17_2","volume-title":"The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3881-y"},{"key":"e_1_3_2_19_2","volume-title":"WHO endorses new rapid tuberculosis test","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. 2010. WHO endorses new rapid tuberculosis test. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_20_2","volume-title":"Policy update. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. 2013. Policy update. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_21_2","volume-title":"Next-generation Xpert MTB\/RIF Ultra assay recommended by WHO","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Next-generation Xpert MTB\/RIF Ultra assay recommended by WHO. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_22_2","volume-title":"Module 3: Diagnosis\u2014rapid diagnostics for tuberculosis detection","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. 2020. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis\u2014rapid diagnostics for tuberculosis detection. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/publications\/i\/item\/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection. Accessed 12 August 2020."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009593.pub4"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(19)30370-4"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30474-7"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30649-8"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(19)30550-x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4749-x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.07.027"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012768.pub2"},{"key":"e_1_3_2_31_2","volume-title":"Global health technologies: time to re-think the \u2018trickle down\u2019 model","author":"Pai M","year":"2020","unstructured":"Pai M. 2020. Global health technologies: time to re-think the \u2018trickle down\u2019 model. Forbes."},{"key":"e_1_3_2_32_2","first-page":"1","volume-title":"India moving forward in research towards new tools for tuberculosis","author":"Indian Council of Medical Research","year":"2017","unstructured":"Indian Council of Medical Research. 2017. India moving forward in research towards new tools for tuberculosis, p 1\u20132. Government of India, New Delhi, India."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051121"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614915"},{"key":"e_1_3_2_35_2","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: Treatment\u2014drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. 2020. WHO consolidated guidelines on tuberculosis. Module 4: Treatment\u2014drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland. who.int\/publications\/i\/item\/9789240007048. Accessed 2 July 2020."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"e_1_3_2_37_2","volume-title":"Pipeline report: tuberculosis diagnostics","author":"Treatment Action Group","year":"2019","unstructured":"Treatment Action Group. 2019. Pipeline report: tuberculosis diagnostics. Treatment Action Group, New York, NY."},{"key":"e_1_3_2_38_2","first-page":"S211","article-title":"Diagnosis of pulmonary tuberculosis by oral swab analysis (OSA): optimisation and development of non-sputum, point-of-care methods","volume":"23","author":"Ortega C","year":"2019","unstructured":"Ortega C, Wood R, Murton H, Andama A, Cattamanchi A, Dixon R, Morgan G, Madan D, Somoskovi A, Cangelose G. 2019. Diagnosis of pulmonary tuberculosis by oral swab analysis (OSA): optimisation and development of non-sputum, point-of-care methods. Int J Tuber Lung Dis 23:S211.","journal-title":"Int J Tuber Lung Dis"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41074-8"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0550"},{"key":"e_1_3_2_41_2","volume-title":"UNITAID end-of-project evaluation: TB GeneXpert\u2014scaling up access to contemporary diagnostics for TB","author":"Unitaid","year":"2017","unstructured":"Unitaid. 2017. UNITAID end-of-project evaluation: TB GeneXpert\u2014scaling up access to contemporary diagnostics for TB. Unitaid, Geneva, Switzerland."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002597"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep25330"},{"key":"e_1_3_2_44_2","first-page":"914","article-title":"Rapid, accurate determination of multidrug resistance in M. tuberculosis isolates and sputum using a biochip system","volume":"13","author":"Guo Y","year":"2009","unstructured":"Guo Y, Zhou Y, Wang C, Zhu L, Wang S, Li Q, Jiang G, Zhao B, Huang H, Yu H, Xing W, Mitchelson K, Cheng J, Zhao Y. 2009. Rapid, accurate determination of multidrug resistance in M. tuberculosis isolates and sputum using a biochip system. Int J Tuber Lung Dis 13:914\u2013920.","journal-title":"Int J Tuber Lung Dis"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01075-2016"},{"key":"e_1_3_2_46_2","volume-title":"Evaluation of centralized assays for TB detection and detection of resistance to rifampicin and isoniazid: WHO Technical Expert Consultation Report","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Evaluation of centralized assays for TB detection and detection of resistance to rifampicin and isoniazid: WHO Technical Expert Consultation Report. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2015.05.010"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-59"},{"key":"e_1_3_2_49_2","volume-title":"Cobas(R) MTB: nucleic acid test for use on the Cobas(R) 6800\/8800 systems","author":"Roche Molecular Systems","year":"2018","unstructured":"Roche Molecular Systems. 2018. Cobas(R) MTB: nucleic acid test for use on the Cobas(R) 6800\/8800 systems. Roche Molecular Systems, Basel, Switzerland."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00241-16"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz932"},{"key":"e_1_3_2_52_2","unstructured":"FIND. 2020. Diagnostics pipeline tracker: tuberculosis on FIND. https:\/\/www.finddx.org\/dx-pipeline-status\/."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00358-17"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00062-6"},{"key":"e_1_3_2_55_2","volume-title":"Technical guide on next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Technical guide on next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_56_2","volume-title":"Relational sequencing TB data platform [website]","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Relational sequencing TB data platform [website]. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-14"},{"key":"e_1_3_2_58_2","volume-title":"Deeplex(R) Myc-TB: from clinical samples to drug resistance profile","author":"Genoscreen","year":"2019","unstructured":"Genoscreen. 2019. Deeplex(R) Myc-TB: from clinical samples to drug resistance profile. Genoscreen, Lille, France."},{"key":"e_1_3_2_59_2","volume-title":"TGen and ABL plan global rollout of advanced test for TB, one of the world's most deadly pathogens","author":"Yozwiak S","year":"2019","unstructured":"Yozwiak S. 2019. TGen and ABL plan global rollout of advanced test for TB, one of the world's most deadly pathogens. TGen, Phoenix, AZ."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30073-2"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0214-5"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00298-17"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1813907"},{"key":"e_1_3_2_64_2","volume-title":"National strategic plan for tuberculosis elimination 2017\u20132025","author":"Revised National Tuberculosis Control Programme","year":"2017","unstructured":"Revised National Tuberculosis Control Programme. 2017. National strategic plan for tuberculosis elimination 2017\u20132025. Directorate General of Health Services, New Delhi, India."},{"key":"e_1_3_2_65_2","volume-title":"National Institute for Communicable Diseases annual overview 2018\/2019","author":"National Institute for Communicable Diseases","year":"2018","unstructured":"National Institute for Communicable Diseases. 2018. National Institute for Communicable Diseases annual overview 2018\/2019. National Institute for Communicable Diseases, Capetown, South Africa."},{"key":"e_1_3_2_66_2","volume-title":"Fiocruz establishes partnership with Chinese scientific institutions","author":"Fiocruz de Not\u00edcias A","year":"2018","unstructured":"Fiocruz de Not\u00edcias A. 2018. Fiocruz establishes partnership with Chinese scientific institutions. Oswaldo Cruz Foundation, S\u00e3o Paulo, Brazil."},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00632-20"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002794"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30041-0"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41182-020-00219-6"},{"key":"e_1_3_2_71_2","volume-title":"Coronavirus (COVID-19) update: FDA issues first emergency use authorization for point of care diagnostic","author":"United States Food and Drug Administration","year":"2020","unstructured":"United States Food and Drug Administration. 2020. Coronavirus (COVID-19) update: FDA issues first emergency use authorization for point of care diagnostic. United States Food and Drug Administration, Atlanta, GA."},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00938-20"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01187-20"},{"key":"e_1_3_2_74_2","volume-title":"New Launch: truenat SARS CoV-2 chip-based real time PCR test for COVID-19","author":"Molbio Diagnostics Private Limited","year":"2020","unstructured":"Molbio Diagnostics Private Limited. 2020. New Launch: truenat SARS CoV-2 chip-based real time PCR test for COVID-19. Molbio Diagnostics Private Limited, Goa, India."},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201702-0278OC"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193988"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001760"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trw056"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30458-3"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30493-5"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000755"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.15412.1"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151073"},{"key":"e_1_3_2_84_2","unstructured":"Stop TB Partnership McGill International TB Centre Arcady Group. 2020. Re-Imagining TB Care. https:\/\/www.reimaginingtbcare.org\/. Accessed 12 August 2020."},{"key":"e_1_3_2_85_2","volume-title":"The use of the Xpert MTB\/RIF assay for the diagnosis of TB. Meeting Report","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. The use of the Xpert MTB\/RIF assay for the diagnosis of TB. Meeting Report. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/tb\/laboratory\/xpert_report_2016.pdf. Accessed 12 August 2020."},{"key":"e_1_3_2_86_2","volume-title":"New rapid molecular test for tuberculosis can simultaneously detect resistance to first- and second-line drugs","author":"FIND","year":"2020","unstructured":"FIND. 16 July 2020. New rapid molecular test for tuberculosis can simultaneously detect resistance to first- and second-line drugs. FIND, Geneva, Switzerland. https:\/\/www.finddx.org\/newsroom\/pr-16jul20\/."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01582-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01582-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T05:37:51Z","timestamp":1646458671000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01582-19"}},"subtitle":[],"editor":[{"given":"Colleen","family":"Suzanne Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":85,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9,22]]}},"alternative-id":["10.1128\/JCM.01582-19"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01582-19","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,22]]},"assertion":[{"value":"2020-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01582-19"}}